The AIM-HI Accelerator Fund (AIM-HI) brings together a worldwide community of leaders in oncology to bridge the gap between laboratory discoveries and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients’ lives.…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today that Mr. Lance Kawaguchi, CEO of Cure Brain Cancer Foundation, has been appointed as a strategic…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today the launching of its first Beacon Award for Women Leaders in Oncology. This award will be an…
The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture Competition! These innovative oncology start-ups have been selected from an exceptional pool of applications submitted by women scientist-entrepreneurs worldwide. The AIM-HI Women’s Venture Competition, now…
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia. ARB202 is an innovative bispecific antibody drug developed by AIM-HI Portfolio Company Arbele, a biotech company based in the Hong Kong Science and Technology Park.…
The year 2021 saw an unprecedented triumph of science as the world witnessed the fastest vaccine development in history. That is the result of decades of investments in basic cancer research. The AIM-HI Accelerator Fund has made decisive progress in…
We have great news to share! The 2022 AIM-HI Women’s Venture Competition is Now Open for Applications! This unique funding program, now in its third year, provides investment, coaching, and networking opportunities to women-led oncology startups. Companies with a woman…
The AIM-HI Accelerator Fund is fiercely dedicated to accelerating the commercialization of innovative lab breakthroughs into life-saving new therapies and technologies. These words evoke a pathway. A pathway of progress that connects cancer research lab breakthroughs to game-changing novel technologies.…
The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee…
Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and…
